The Conversation (0)
Ablynx (Nasdaq: ABLX) today announced its financial results for the year ended 31st December 2017, which have been prepared in accordance with IFRS as issued by the IASB and adopted by the European Union, business highlights year-to-date and the outlook for the remainder of the year. As quoted in the press release: Dr Edwin Moses, CEO of …
Ablynx (Nasdaq: ABLX) today announced its financial results for the year ended 31st December 2017, which have been prepared in accordance with IFRS as issued by the IASB and adopted by the European Union, business highlights year-to-date and the outlook for the remainder of the year.
As quoted in the press release:
Dr Edwin Moses, CEO of Ablynx said:
“We experienced many momentous moments this year including the compelling Phase III results for our lead product caplacizumab and our successful US initial public offering. Caplacizumab has the potential to change the lives of patients affected by aTTP, a devastating disease for which there is currently no approved drug available. We are proud to be pioneers in the treatment of aTTP and are working with the regulatory authorities to obtain marketing approval and make caplacizumab rapidly available to patients.”
